An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Trial Profile

An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs Selinexor (Primary) ; Dexamethasone; Ixazomib
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Jan 2018 Planned number of patients changed from 24 to 38.
    • 17 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.
    • 17 Jan 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top